research reports and media, page-2398

Indeed it would be a good stepping stone before the main game....

It would give us credibility
It would give us at least some funding
It would assist greatly for others that might be circling around looking at our OA situation and what we can do there.


Logically MPS is a very niche and specialised area and it would make sense to partner to get more expertise to lead the program and form a decent collaboration taking us forward.

There is already some good data out now which provides the potential suitor a look through as to what our drug can do and just how complimentary it will be as a worthwhile benefit and feature in their suite.

While we don't know the timing of this and there are a few players in the market, you'd think that once they get a whiff, at least a few of them would be interested in forming a deal, its a worthy point of difference they would acquire in an area of the market that probably hasn't changed too much in recent years.